BioLife Solutions, Inc. $BLFS Shares Acquired by Tudor Investment Corp ET AL

Key Points

• Tudor Investment Corp ET AL boosted its stake in BioLife by 85.2% in Q3, acquiring 51,217 shares to hold 111,356 shares (about 0.23% of the company) worth roughly $2.84 million.
• Analysts are generally positive with a consensus rating of "Moderate Buy" and an average target of $32.00, though opinions range from Strong Buy to Sell and some targets sit near $32–$34.
• Shares are trading below recent averages (opened at $19.74, down ~3.6%; 50-day $20.74, 200-day $23.96) and insiders sold about 99,641 shares last quarter — including a 96,923-share sale by Karen Foster — leaving insiders owning 2.20%.

Tudor Investment Corp ET AL grew its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 85.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 111,356 shares of the medical equipment provider's stock after purchasing an additional 51,217 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.23% of BioLife Solutions worth $2,841,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of BLFS. Connors Investor Services Inc. acquired a new position in shares of BioLife Solutions in the 3rd quarter valued at $224,000. CIBC Bancorp USA Inc. acquired a new position in shares of BioLife Solutions during the third quarter worth $1,064,000. PharVision Advisers LLC purchased a new position in BioLife Solutions in the 3rd quarter valued at about $316,000. Quarry LP boosted its holdings in BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider's stock valued at $54,000 after purchasing an additional 713 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of BioLife Solutions by 2.9% during the 3rd quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider's stock valued at $707,000 after buying an additional 783 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on BLFS shares. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of BioLife Solutions in a research note on Monday, December 29th. Wall Street Zen upgraded shares of BioLife Solutions from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Zacks Research upgraded BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 23rd. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a report on Monday, January 5th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioLife Solutions presently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

BioLife Solutions Trading Down 3.6%

Shares of NASDAQ BLFS opened at $19.74 on Friday. The business has a 50-day moving average price of $20.74 and a two-hundred day moving average price of $23.96. BioLife Solutions, Inc. has a one year low of $17.86 and a one year high of $29.62. The firm has a market capitalization of $953.44 million, a PE ratio of -179.44 and a beta of 2.00.

Insider Buying and Selling

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of the company's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $20.15, for a total value of $1,952,998.45. Following the transaction, the insider directly owned 113,742 shares of the company's stock, valued at $2,291,901.30. This represents a 46.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 99,641 shares of company stock valued at $2,009,000 in the last quarter. Insiders own 2.20% of the company's stock.

About BioLife Solutions

BioLife Solutions NASDAQ: BLFS specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.